 LOS GATOS, Calif., July 12, 2021 PRNewswire -- Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level 20ngmL. 